Marseilles, France, March 2, 2011 -- Innate Pharma (the ?Company? - Euronext Paris: FR0010331421 – IPH) reports today its consolidated financial results for the year ending December 31, 2010. Unaudited consolidated
financial statements are attached to this press release.
The key elements of these results are as follows:
- Operating revenue amounting 4.3 million euros (vs. 7.7 million euros in 2009), primarily
from a research tax credit as well as, to a lesser extent, collaboration agreements with
Novo Nordisk A/S;
- Operating expenses amounting to 18.0 million euros (vs. 23.3 million euros in 2009), of
which about 80% is in research and development;
- Net loss amounting to 13.7 million euros (vs. 14.6 millions euros in 2009); and
- Cash, cash equivalents and current financial instruments amounting to 34.6 million euros as at
December 31, 2010, with 7.5 million euros in debt, including 4.4 million euros for the long-term
financing of property and equipment. Based on its current programs, the Company estimates
that this situation corresponds to a cash runway into 2013.
In the course of 2010, the Company progressed in the clinical development of the IPH 21
program, with the continuation of the ongoing trials and the set-up of new Phase II trials in
multiple myeloma with IPH 2101, as well as the initiation of a first clinical trial with IPH 2102.
It has also continued its effort on new targets validation in the field of innate immunity and the
development of antibodies targeting them.
At the beginning of 2011, Novo Nordisk A/S filed a new clinical trial application for IPH 2201, which
is expected to be the third program arising from the collaboration between the two companies to
enter clinical trials. This achievement triggered the payment of a milestone to Innate Pharma.
Lastly, within the context of a strategic review of its portfolio and after discussions with potential
partners relating to a development partnership for IPH 1101, the Company has concluded that
further pursuit of partnering activities for IPH 1101 is not warranted. The Company has
consequently decided to focus its efforts on antibody programs, consistently with its positioning.
“2010 has been a year of major progress and renewed interest for cancer immunotherapy,
notably with the emergence of a new class of antibodies modulating immune regulatory
mechanisms, which could transform the treatment of cancer and inflammatory disorders in the
next decade. Our anti-KIR antibody is one of the most advanced candidate of this class and as
such, is attracting a lot of attention from the medical community and from the industry”, said
Hervé Brailly, CEO of Innate Pharma.
François Romagné, Innate Pharma’s EVP and CSO of Innate Pharma, added: “We progress in
the building of our portfolio of antibodies targeting the regulatory pathways of innate immunity
cells. A fourth drug candidate has just been qualified to enter clinical development by our
partner Novo Nordisk A/S and we are confident in our unique scientific positioning to yield new
drug candidates for cancer and inflammation.”
The unaudited consolidated annual IFRS financial statements at December 31, 2010 as well as
the management discussion on these results are in appendix at the end of this document.
The table below summarizes the consolidated income statement for the 12-month period
ending December 31, 2010, with a comparison to the same period in 2009:
Update on 2010 achievements and outlook for 2011/2012:
- IPH 21 program (anti-KIR monoclonal antibody):
In 2010, Innate Pharma continued the set-up of the Phase II program of IPH 2101 in multiple
myeloma. Two trials sponsored by Innate Pharma are currently ongoing in this indication:
REMYKIR (IPH 2101-201 - single agent, maintenance) and KIRMONO (IPH 2101-203 - single
agent, smoldering myeloma). A third trial, KIRIMID (IPH 2101-202 - combination with
lenalinomide, relapse) is open for patient recruitment. Another Phase II trial, sponsored by the
National Cancer Institute, is ongoing (single agent, smoldering myeloma).
The Phase I clinical trial extension with IPH 2101 in acute myeloid leukaemia is also ongoing.
The Company has also begun a Phase I clinical trial with IPH 2102, a recombinant form of the
same anti-KIR monoclonal antibody as IPH2101, produced in a cell-line suited for industrial
production and which will be the actual candidate for registration.
The final results for the Phase I study with IPH 2101 in multiple myeloma will be presented at
the ?International Myeloma Workshop? in Paris, in May 2011. REMYKIR results are expected at
the end of 2011/beginning of 2012. The results of the other ongoing trials sponsored by Innate
Pharma are expected at the end of 2012/beginning of 2013.
- IPH 2201 (NN8765):
In the beginning of 2011, Novo Nordisk A/S filed a first clinical trial application for IPH 2201, a
monoclonal antibody developed in inflammation and auto-immune diseases, and licensed by
Innate Pharma to Novo Nordisk A/S. The application filing triggered a milestone payment from
Novo Nordisk A/S to Innate Pharma.
IPH 2201 is expected to enter clinical trial in 2011, thus becoming the third monoclonal
antibody arising from the collaboration with Novo Nordisk A/S to reach this stage. Innate
Pharma is eligible to milestone payment for the development of IPH 2201 and royalties on
future sales of IPH 2201.
- IPH 1101:
In July 2010, the Company announced the final results of the Phase I/II trial with IPH 1101 in
folicullar lymphoma, revealing a possible clinical benefit of the combination IPH 1101,
rituximab and IL-2. Based on these results as well as on the demonstration of an anti-viral
effect of IPH 1101 in type C viral hepatitis, the Company engaged into an active search for a
development partner while maintaining its previous decision not to invest further financial
resources in the program. As no interest materialized for the industrial development of the
program, the Company has decided, within the frame of its strategic review of its portfolio, to
stop its efforts for the gamma delta program. The Company will continue to maintain certain
intellectual property assets in relation to the gamma delta program which could lead to a
future recognition of revenue.
- Pre-clinical programs:
- In the course of 2010, the Company completed its shift towards the research and
development of antibody drug candidates targeting the control of activation pathways of
innate immunity cells for cancer and inflammatory indications. Several targets are currently in
validation. The Company expects to start lead candidate optimization for a new program in
- The IPH 41 program targeting the KIR3DL2 molecule is ongoing (cutaneous T cell lymphoma
– Sezary syndrome, preclinical validation). A first antibody candidate, IPH 4101, did not
achieve the preset criteria to qualify for regulatory development, despite enhanced
cytotoxicity properties by its production with Vivalis EB66® cell line. Other candidates against
the target have been generated and are currently in validation.
A meeting for fund managers, financial analysts and journalists will be held this day at
4:00pm (CET) in Paris.
The slideshow will be available on the Company’s website when the meeting begins
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy
drugs for cancer and inflammatory diseases.
The Company specializes in the development of new monoclonal antibodies targeting receptors
and pathways controlling the activation of innate immunity cells. Its most advanced drug-
candidate is IPH 2101, an anti-KIR monoclonal antibody potentiating NK cells activation
currently in Phase II clinical trials in hematologic cancers. Two of its antibody programs in
chronic inflammation are out-licensed to Novo Nordisk A/S.
Innate Pharma’s key expertise is in immunopharmacology and antibody technology. The
Company has implemented in-house a large panel of molecular and cellular assays and in vivo
models for assessing the pharmacodynamics and pharmacotoxicology of drug candidates. In
addition, Innate Pharma has access to a very large set of unique research tools in cellular
immunology through its worldwide network of scientific collaborations.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in
Marseilles, France, and had 86 employees as at December 31, 2010.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
This press release contains certain forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these forward-looking statements are subject
to numerous risks and uncertainties, which could cause actual results to differ materially from
those anticipated. For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from those contained in
the forward-looking statements, please refer to the Risk Factors (?Facteurs de Risque") section of
the Document de Reference prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a
solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
Alize Public Relations
Phone: +33 (0)1 41 22 07 31
Mobile: +33 (0)6 64 18 99 59
Innate Pharma SA
The audit procedures from our statutory auditors are in progress to date. The unaudited
consolidated financial statements have been approved by the Company's Executive Board on
February 28, 2011. These statements were reviewed by the Company's Supervisory Board on
February 28, 2011 and will be submitted for approval to the Shareholders' General Meeting on
June 29, 2011.
Innate Pharma’s financial annual report, included in the reference document, will be available
in the second quarter.
Management discussion on unaudited annual results for 2010:
Currently, operating revenue is derived mainly from government financing for research
expenditure as well as, to a lesser extent, collaboration and licensing agreements. Our
operating revenue was 7.7 million euros and 4.3 millions euros for the fiscal years ending on
December 31, 2009 and 2010, respectively, from the following sources:
Revenue from collaboration and licensing agreements
Revenue from collaboration and licensing agreements for the fiscal years ending on
December 31, 2009 and 2010 come from collaboration and licensing agreements signed with
Novo Nordisk A/S.
Variations in revenue for the fiscal years ending on December 31, 2009 and 2010 are
explained by the end of these agreements.
Government financing for research expenditure
The table below details government financing for research expenditure for the fiscal years
ending December 31, 2009 and 2010:
For the fiscal year 2009, 66 thousand euros, 509 thousand euros and 81 thousand euros were
booked respectively for ANR grants, for two "Lyon Biopôle" cluster grants and for an Oséo ISI
For the fiscal year 2010, the Company booked mainly a "Lyon Biopôle" cluster grant of
287 thousand euros.
These subsidies directly impact our income statement, as opposed to repayable loans which
are recorded as debt and thus only impact our balance sheet.
Since the fiscal years ending on December 31, 2008, the calculation of the research tax credit
is based on 30% of the amount of eligible expenses for the fiscal year.
The research tax credit is usually reimbursed by the government during the fourth fiscal year
following the one for which it was booked in the income statement, provided that it is not deducted
from taxes due by the Company. In the context of the French finance bills for 2010 and 2011, the
French government has decided to immediately refund all research tax credit balance receivables
as at December 31, 2009 and 2010. The Company has received in early 2010 the refund of its
entire research tax credit balance as at December 31, 2009, amounting to 3.8 million euros and
will ask for the immediate refund of its 2010 research tax credit in early 2011.
For the year 2011, only the small and medium sized companies according to the European Union
criteria are illegible to the anticipated reimbursement of their debt related to the research tax
credit. Management ensured that the Company is a SME according to the European Union
criteria and can therefore benefit from the anticipated reimbursement.
Since 2008, repayable grants received are deducted from the basis of calculation of the research
tax credit. These amounted respectively 1,200 and 91 thousand euros in 2009 and 2010. In
parallel, the Company conducted more research outside of the European Union, notably in the
USA, and these research expenses are not eligible for the research tax credit calculation.
Our research and development expenses were 18.0 million euros and 14.0 million euros for the
fiscal years ending on December 31, 2009 and 2010, respectively. These expenses
represented 78% of our net operating expenses for the fiscal years ending on December 31,
2009 and 2010. The decrease in research and development expenses between 2009 and 2010
is mostly explained by a decrease in subcontracting in relation to the end of the clinical
program of IPH 1101, as well as a decrease in the intellectual property costs.
General and administrative expenses include expenses for employees not working on research
and development, as well as the expenses necessary for the management of the business and
its development. General and administrative expenses were 5.2 million euros and 3.9 million
euros for the fiscal years ending on December 31, 2009 and 2010, respectively. This expense
represents a total of 22% of the net operating expenses for the fiscal years ending on
December 31, 2009 and 2010. The decrease in general and administrative expenses is mostly
related to the decrease in share-based payments.
Cost of supplies and consumable materials
The cost of supplies and consumable materials totalled 1.7 million euros and 2.7 million euros
for the fiscal years ending on December 31, 2009 and 2010, respectively.
Cost of supplies and consumable materials are broken down into two categories: (i) costs for
manufacturing pharmaceutical ingredients and products and (ii) purchasing of products and
consumables, broken down as follows for the fiscal years ending on December 31, 2009 and
As we have no manufacturing facilities, we outsource the entire production process. Our most
advanced products, IPH 1101 and IPH 2101, are manufactured by different subcontractors in
several stages, from manufacturing the pharmaceutical ingredients to the intermediate stage
of production, and eventually to the delivery of the pharmaceutical product.
The increase in the cost of manufacturing products between 2009 and 2010 is explained by the
consumption of pharmaceutical product within the frame of our different ongoing clinical trials
for the IPH 21 program.
Other consumable purchases include the cost of products consumed in our laboratories and by
third parties with whom we collaborate notably during our clinical trials. They are summarized
in the table below:
Consumable purchases mainly relate to laboratory reagents. The decrease of this line item in 2010
compared to 2009 mostly results from an evolution of the consumable expenses structure, with
the decrease of the most expensive consumables.
Intellectual property expenses
Intellectual property expenses were 1.6 million euros and 0.7 million euros for the fiscal years
ending December 31, 2009 and 2010, respectively.
These costs include the cost of filing and protecting our patents (including patents for which we
acquired the rights from third parties and assumed the costs for filing and protection under the
terms of the agreements with the patent owners) as well as the costs for obtaining an option or
license for intellectual property. Application of IAS 38, in light of the degree of maturity of the
Company and the uncertainty that exists as to the outcome of our research and development
projects, requires us to recognize all intellectual property expenses for the fiscal year in which we
incur the costs.
The costs of filing and protecting our patents came to 0.1 million euros for the fiscal years ending
on December 31, 2009 and 2010. We filed 37 and 18 patent applications (initial applications or
applications for extensions for our patents or patents we hold jointly with others) during the fiscal
years ending on December 31, 2009 and 2010, respectively.
The costs of obtaining an option or license or acquiring intellectual property rights came to
1.5 million euros and 0.6 million euros during the fiscal years ending on December 31, 2009 and
2010, respectively. In 2009, we had to pay significant milestones to some of our licensors in
connection to successful milestones with our drug candidates. In 2010, the intellectual property
expenses mainly related to maintenance costs for our patents.
Sub-contracting expenses involve discovery research costs (financing research conducted
externally, particularly academic research, antibody humanization technologies, manufacturing
process development, etc.), pre-clinical development (pilot manufacturing, tolerance and
pharmacology studies, etc.) and clinical costs (clinical trial management, etc.) outsourced to
Sub-contracted clinical services primarily concern services for monitoring trials, as well as
data, statistics and pharmacolovigilance management outsourced to clinical research
companies (Contract Research Organizations, or "CRO"). The decrease in 2010 compared to
2009 is mainly explained by the end of the clinical program with IPH 1101. The costs related to
this program were 3.5 million euros and 0.3 million euros during the fiscal years ending on
December 31, 2009 and 2010, respectively.
Scientific consultancy and services consist of costs related to outside consultants assisting in
the research and development of our products. It also covers fees paid to members of our
Scientific committee. The decrease in this line item in between 2009 and 2010 is mostly
explained by regulatory fees in 2009, in relation to the initiation of our Phase II program with
In 2008, the Company moved to new, lease-financed premises in Marseille. The decrease in
leases, maintenance and utility costs between 2010 and 2009 is mainly explained by residual
costs in 2009 in relation to the previous premises of the Company, for 0.2 millions euros.
Travel and conference costs include expenses for employee travelling and attending
conferences, particularly scientific, medical, business development and financial conferences.
The participation to these meeting aims at maintaining the visibility, the expertise, and the
credibility of the Company within these different communities.
Non-scientific consultancy are mostly fees paid to auditing firms, to our certified public
accountant for his assistance in accounting, tax and employee matters, our lawyers for their
assistance in negotiating collaboration and licensing agreements and general counselling
assistance, to business strategy or development consultants and to recruitment fees.
Marketing, communications and public relations costs cover fees for our communication and
public relations consultants, costs of developing and producing communication tools, such as
our website and business reports.
The decrease in the non scientific ?Other purchases and external expenses? line item between
2009 and 2010 is partly explained by the expense reduction program decided in early 2009
and pursued in 2010.
Employee benefit other than share-based compensation
Employee benefit other than share-based compensation came to 6.7 million euros and
6.2 millions euros for the fiscal years ending on December 31, 2009 and 2010, respectively.
This includes salaries and social benefit costs.
On average we had 84.5 and 83.0 employees for the fiscal years ending on December 31,
2009 and 2010, respectively.
Employee expenses (salary and social costs) divided by the average number of employees
over the year, i.e. the average cost per employee, showed an amount of 80 thousand euros
and 75 thousand euros per employee for the fiscal years ending on December 31, 2009 and
In 2010, the decrease in the average employee benefits costs is explained by (i) additional
bonuses paid in 2009 in relation to a increased attainment of pre-set goals, as well as (ii) in
2009, increase in some compensation packages and redundancy costs.
Share-based compensation came to 1.8 million euros and 0.03 million euros for the fiscal years
ending on December 31, 2009 and 2010, respectively. These are costs associated with the
potential compensation given to managers, employees and consultants through stock-options,
warrants and free shares which would give them ownership in our share capital in the future.
This potential, non-cash compensation, is accounted as an expense in accordance with the
IFRS 2 standard.
The decrease in share-based compensation between the two periods under review is explained
by the acceleration, in early 2009, of the vesting conditions of the free shares distributed in
Depreciation and amortization
These costs came to 1.1 million euros for the fiscal years ending on December 31, 2009 and
2010. The new premises of the Company are amortized since January 1, 2009. This expense
amounted 373 thousand euros and 374 thousand euros for the fiscal years ending on
December 31, 2009 and 2010, respectively.
Other income and expenses, net
We had a net cost of 0.3 million euros and 0.2 million euros for the fiscal years ending on
December 31, 2009 and 2010 respectively. Other income and expenses mainly include certain
indirect taxes, as well as exceptional income and expenses.
Net financial income
Our net financial income came to 0.9 million euros and is nil for the fiscal years ending on
December 31, 2009 and 2010, respectively. The 2009 profit mainly resulted from a 1.1 million
euros gain following the sale of financial instruments.
Thus far, we have not relied much on bank loans or lease-financing and have had positive
banks balances, a situation which explains our net positive financial income in the period under
review. Our cash investment policy favours the absence of risk on principal and, wherever
possible, guaranteed minimum performance. We invest mostly in money market financial
The average balance of current cash investments and current financial instruments was 41.5
million euros and 41.9 millions euros for the fiscal years ending on December 31, 2009 and
2010, respectively *
Because of the deficits reported for the last three fiscal years, we have not paid corporate tax.
No deferred tax asset has been recorded as there is minimal likelihood of recovery. The
research tax credit is not a corporate tax income according to IFRS. It is booked directly as
Net income/(loss) per share
The net loss per authorized and issued share came to 0.56 euros and 0.36 euros for the fiscal
years ending on December 31, 2009 and 2010, respectively.
Balance sheet items:
Cash, cash equivalent and current financial instruments amounted to 34.6 million euros as of
December 31, 2010, compared with 49.2 million euros as of December 31, 2009.
Since its incorporation in 1999, the Company has been primarily financed by issuing new
securities. The Company has also generated cash flow from its licensing activities (mostly in
relation to the agreements with Novo Nordisk A/S), government financing for research
expenditure and repayable government financing (Oséo-Anvar). Financial debt amounted to
7.5 million euros as of December 31, 2010, out of which 4.4 million euros in relation to the
long-term financing of property and equipment.
Post balance sheet event:
Beginning of 2011, Innate Pharma received a milestone payment from Novo Nordisk A/S
related to the achievement of a pre-specified development milestone with the drug candidate
IPH 2201 (NN8765).
Risk factors affecting the Company are presented in paragraph 4 of the latest ?Document de
Référence? submitted to the French stock-market regulator, the ?Autorité des Marchés
Financiers? on April 23, 2010.
Annual financial report for 2010 and “Reference Document”:
The Company intends to file its 2010 annual financial report as well as its ?Reference
Document? for the year so that these documents are made public in the second quarter of